Semaglutide is linked to a reduced risk for Alzheimer’s disease-related dementia in patients with diabetes vs other antidiabetic drugs, a new study suggests.

Beyond helping diabetes patients lose weight and control blood sugar, semaglutide appears to cut dementia risk by nearly half ...

Eli Lilly And Co.'s (LLY) investigational oral GLP-1 receptor agonist, orforglipron, demonstrated compelling efficacy and a safety profile aligned with that of injectable GLP-1 therapies, according to ...

Four out of 10 U.S. adults ages 18 to 44 have insulin resistance—and most don’t even know it. But what is insulin resistance, ...

In this episode of 'Booked', top endocrinologist Dr. Ambrish Mithal unpacks the world of new-age weight-management drugs, ...

GLP-1 agonists like Wegovy, Ozempic, and Mounjaro might benefit heart and brain health—but research suggests they might also ...

Some supplements can support healthy weight loss, but they’re not a magic fix, says Raj Dasgupta, M.D., a quadruple board-certified internist at Huntington Health Hospital in Pasadena, California.

The WHO’s guidance advising against the use of nonsugar sweeteners for weight loss is based on a systematic review published in April 2022 conducted by the organization’s researchers, which ...

How do weight loss drugs like Ozempic and Mounjaro work? Administered as weekly jabs, these drugs – often called GLP-1 agonists – mimic the hormones our bodies release when we eat to help ...

Among those who adhered to treatment, the high-dose group achieved an average weight loss of 20.7%, compared to 17.5% with the lower dose and 2.4% in the placebo group.

"Read this in-depth Gluco6 reviews based on 45 days of personal use. Discover ingredients, benefits, side effects and pricing ...